

Thursday, March 30, 2006

14:00 - 15:30

Hall A

THE PHILOSOPHY OF DRUG DEVELOPMENT

Chairperson: **Roger Vogel, USA**

Abstract Page No

- | | | |
|-------|---|---|
| 14:00 | INTRODUCTION: THE ISSUES FOR THE PATIENT, THE PHYSICIAN, THE REGULATORS AND THE PHARMACEUTICAL INDUSTRY
R. Vogel, Sarasota, FL, USA | |
| 14:15 | QUANTIFICATION OF VISUAL FUNCTION AND VISUAL CHANGE-INSTRUMENTS AND MEASURES
M.E. Verdugo, Waterford, CT, USA | 1 |
| 14:30 | VALUE-BASED MEDICINE: THE NEW PARADIGM
M. Brown, Flourtown, PA, USA | 1 |
| 14:45 | THE REQUIREMENT FOR EFFICACY IN ASSESSMENT OF DRUGS FOR SIGHT THREATENING DISEASES
W. Chambers, Silver Spring, MD, USA | |
| 15:00 | WHO DECIDES AVAILABILITY OF CARE?
J.M. Bottomley, Letchworth Garden City, UK | 1 |
| 15:15 | TREATMENT OF RETINAL DISORDERS: CHALLENGES FOR THE SMALL COMPANY
G.D. Novack, San Rafael, CA, USA | 1 |
| 15:30 | COFFEE BREAK, EXHIBITION AND POSTER VIEWING | |

16:00 - 16:45

Hall A

EUROPEAN DRUG DEVELOPMENT

Chairperson: **Jose G. Cunha-Vaz, Portugal**

- | | | |
|-------|--|---|
| 16:00 | A EUROPEAN NETWORK OF CERTIFIED CLINICAL TRIALS CENTRES OF OPHTHALMOLOGY - EVI.CT.SE
J.G. Cunha-Vaz, Coimbra, Portugal | 3 |
| 16:10 | THE ISSUE OF PRESERVATIVE EFFICACY TESTING REQUIREMENTS IN THE DEVELOPMENT OF OPHTHALMIC DRUGS IN EUROPE
K.H. Geldsetzer, B.R. Matthews, F.S. Skinner, Germering, Germany, Hemel Hempstead, UK, Basel, Switzerland | 4 |
| 16:20 | NEW REGULATIONS FOR CLINICAL STUDIES IN EUROPE
Y. Geysels, Brussels, Belgium | |
| 16:30 | THE ROLE OF THE CROS IN THE OPHTHALMOLOGICAL DRUG DEVELOPMENT IN EUROPE
P-P. Elena, La Gaude, France | 4 |
| 16:40 | DISCUSSION | |

Thursday, March 30, 2006

14:00 - 14:45

Hall B

OCULAR BLOOD FLOW IN EYE DISEASE

Chairperson: **Alon Harris, USA**

Abstract Page No

14:00 THE IMPORTANCE OF OCULAR BLOOD FLOW IN MACULAR DEGENERATION
A. Harris, Indianapolis, IN, USA

2

14:15 THE EFFECTS OF MEDICATION ON OCULAR BLOOD FLOW
M.R. Lesk, M. Wajszilber, Montreal, Canada

2

14:30 THE IMPORTANCE OF OCULAR BLOOD FLOW IN GLAUCOMA
P.A. Netland, Memphis, TN, USA

2

14:45 - 15:30

Hall B

ALLERGY

Chairperson: **Michael B. Raizman, USA**

14:45 TREATMENT OF SCAR FORMING CONJUNCTIVITIS
N.P. Barney, E.B. Cook, J. Stahl, F.M. Graziano, Madison, WI, USA

2

14:55 THE NEW GENERATION OF ANTI-ALLERGIC EYE DROPS
R. Sgrulletta, M. Coassin, S. Bonini, Rome, Italy

3

15:05 ASSESSMENT OF MAST CELL STABILIZATION IN THE TREATMENT OF ALLERGIC CONJUNCTIVITIS
A. Leonardi, Padua, Italy

3

15:15 THE EFFECTS OF ANTI-ALLERGIC DRUGS ON OCULAR CYTOKINE RESPONSES
V.L. Calder, Y. Ajayi, G. Galatowicz, London, UK

3

15:25 DISCUSSION

15:30 **COFFEE BREAK, EXHIBITION AND POSTER VIEWING**

Thursday, March 30, 2006

16:45 - 17:30

Hall A

OCULAR MICROBIOLOGY - ADVANCES IN DIAGNOSIS AND THERAPY OF OCULAR VIRAL DISEASES

Chairperson: **Irina S. Barequet**, Israel

Abstract Page No

- | | | |
|-------|---|---|
| 16:45 | INTRODUCTION
I.S. Barequet , <i>Tel-Hashomer, Israel</i> | |
| 16:48 | DIAGNOSING OCULAR VIRAL INFECTIONS: PRESENT AND FUTURE
R.P. Kowalski , <i>Pittsburgh, PA, USA</i> | 6 |
| 17:00 | ANTIVIRAL DRUGS
E. De Clercq , <i>Leuven, Belgium</i> | 6 |
| 17:12 | ADVANCES IN OCULAR ANTIVIRAL DEVELOPMENT
E.G. Romanowski , <i>Pittsburgh, PA, USA</i> | 7 |
| 17:24 | DISCUSSION | |

Thursday, March 30, 2006

16:00 - 17:50

Hall B

MACULAR EDEMA

Chairpersons: **George A. Williams, USA**
Jordi Monés, Spain

Abstract Page No

16:00	BIOERODIBLE SUSTAINED-RELEASE SYSTEMS: CHANGING CONCEPTS AND PARADIGMS IN TARGETING EYE DISEASES J.A. Cardillo , Araraquara, Brazil	4
16:10	THE HELICAL COIL DRUG TECHNOLOGY FOR DME E. De Juan , Los Angeles, CA, USA	
16:20	TREATMENT OF DIABETIC MACULAR EDEMA WITH PEGAPTANIB J. Monés , Barcelona, Spain	4
16:30	FLUOCINOLONE ACETONIDE IMPLANT FOR UVEITIS C.E. Pavesio , London, UK	
16:40	SAFETY AND EFFICACY OF AN INTRAVITREAL DEXAMETHASONE BIODEGRADABLE DRUG DELIVERY SYSTEM FOR THE TREATMENT OF PERSISTENT MACULAR EDEMA G.A. Williams , B.D. Kuppermann, J.A. Haller, M.S. Blumenkranz, C. Chou, S.M. Whitcup, Royal Oak, MI, Irvine, CA, Baltimore, MD, Stanford, Irvine, CA, USA	5
16:50	INTRAVITREAL TRIAMCINOLONE FOR MACULAR DISEASES (DME, CRVO, BRVO) I.U. Scott , Hershey, PA, USA	5
17:00	PHARMACOLOGIC RATIONALE FOR INTRAVITREAL CORTICOSTEROIDS IN RETINAL VASCULAR DISEASE J.L. Edelman , Irvine, CA, USA	5
17:10	SAFETY PROFILE OF CORTICOSTEROIDS ON RETINAL CELLS IN VITRO B.D. Kuppermann , R. Narayanan, S. Luthra, L.E. Marques, A. Neekhara, M.C. Kenney, Irvine, CA, USA	6
17:20	INTRAVITREAL INJECTION: TECHNIQUE FOR THE SCORE AND DRCRNET STUDIES I.U. Scott , Hershey, PA, USA	6
17:30	FLUOCINOLONE ACETONIDE IMPLANT FOR DIABETES P.A. Pearson , Lexington, KY, USA	
17:40	RANIBIZUMAB (LUCENTISTM) LIQUID FORMULATION PLUS SAME-DAY VERTEPORFIN PDT IS ASSOCIATED WITH A LOWER INCIDENCE OF OCULAR ADVERSE EVENTS THAN SEQUENTIAL USE OF VERTEPORFIN-PDT AND LYOPHILIZED RANIBIZUMAB S. Michels , U. Schmidt-Erfurth, T. Hohman, The ANCHOR Study Group, The PROTECT Study Group, Vienna, Austria, East Hanover, NJ, USA	5

Friday, March 31, 2006

Hall A

08:00 - 09:00

FREE PAPERS: INFLAMMATION AND EXTERNAL DISEASES

Chairpersons: **Quan Dong Nguyen, USA**
Anthony J. Bron, UK

Abstract Page No

08:00	ORBITAL PSEUDOTUMOR IN A PATIENT WITH METHYLMALONIC ACIDEMIA M. Al-Owain , A. Weber, S. Al-Haddab, H. Kamal, Z. Al-Hassnan, <i>Riyadh, Saudi Arabia</i>	7
08:08	ADALIMUMAB (HUMIRA) THERAPY IN POSTERIOR UVEITIS T. Missotten , J.A.M. van Laar, T. van der Loos, P.M. van Hagen, G.S. Baarsma, <i>Rotterdam, The Netherlands</i>	7
08:16	THE TEN YEAR EXPERIENCE OF IMMUNOMODULATOR LICOPID USE IN THE MANAGEMENT OF INFLAMMATORY EYE DISEASES, INCLUDING DRY EYE Y.F. Maychuk , D.Y. Maychuk, M.A. Kovalevskaya, <i>Moscow, Russia</i>	7
08:24	HAZE CONTROL AND SAFETY PROFILE OF A PRESERVATIVE-FREE 0.1% DEXAMETHASONE IN CLINICAL ROUTINE AFTER PHOTOREFRACTIVE KERATECTOMY L. Spadea , A. Di Gregorio, <i>L'Aquila, Italy</i>	8
08:32	CORNEOPLASTIQUE (TM): GLUES, AMNIOTIC MEMBRANES, SYNTHETICS & LASERS FOR THE ART OF VISION A.C. Gulani , <i>Jacksonville, FL, USA</i>	8
08:40	PTERYGIUM SURGERY: FIBRIN GLUE VERSUS VICRYL SUTURES FOR CONJUNCTIVAL CLOSURE I. Bahar , D. Weinberger, D. Gatton, R. Avisar, <i>Petach Tikva, Israel</i>	8
08:48	PREOPERATIVE TEAR BIOCHEMICAL PROGNOSIS OF DRY EYE APPEARANCE AND IT'S MANIFESTATION PERIODS IN CASES OF REFRACTIVE SURGERY O.A. Káshnikova , V.V. Kourenkov, <i>Moscow, Russia</i>	8
08:56	DISCUSSION	

Hall A

09:00 - 09:45

HIGH THROUGHPUT SCREENING OF NEUROPROTECTIVE THERAPIES

Chairpersons: **Leonard Levin, USA**
Wolf Lagrèze, Germany

09:00	SCREENING OF NEUROPROTECTIVE DRUGS W. Lagrèze , <i>Freiburg, Germany</i>	
09:15	SCREENING SYNTHETIC STEROIDS FOR NEUROPROTECTION OF RETINAL GANGLION CELLS IN GLAUCOMA N. Agarwal , D.M. Kumar, Z.Y. Cai, D.F. Covey, L. Prokai, K. Prokai, J.W. Simpkins, <i>Fort Worth, TX, St. Louis, MO, USA</i>	9
09:30	DIFFERENTIATED RGC-5 CELLS AS A MODEL FOR SCREENING RETINAL GANGLION CELL NEUROPROTECTIVE THERAPIES L.A. Levin , <i>Madison, WI, USA</i>	9

Friday, March 31, 2006

07:30 - 09:00

Hall B

MINI COURSE: ADDRESSING CHALLENGING CASES IN CORNEAL DISORDERS

Chairperson: **Manfred Zierhut**, Germany

Abstract Page No

- 07:30 HSV KERATITIS
M. Zaal, *The Netherlands*
- 08:00 CORNEA AND SYSTEMIC DISORDERS
R. Neumann, *Petach Tikva, Israel*
- 08:30 BULLOUS DERMATITIS AND EYE INVOLVEMENT
M. Zierhut, *Tuebingen, Germany*

09:00 - 09:45

Hall B

OCULAR TOXICOLOGY

Chairperson: **Frederick W. Fraunfelder**, USA

- 09:00 DRUG-INDUCED OCULAR SIDE EFFECTS OF CLINICAL IMPORTANCE
F.W. Fraunfelder, *Portland, OR, USA* 9
- 09:15 OCULAR FUNCTION TESTING IN MULTICENTRE TRIALS: HOW TO MEET THIS CHALLENGE?
E. Zrenner, *Tuebingen, Germany* 9
- 09:30 WHAT ARE THE PREFERRED OCULAR TESTS FOR HUMAN OCULAR TOXICOLOGY?
W. Chambers, *Silver Spring, MD, USA*

Friday, March 31, 2006

09:45 - 10:30

Hall A

NPDR / PDR / NEUROPROTECTION

Chairpersons: **Edgar L. Thomas, USA**
Jose G. Cunha-Vaz, Portugal

Abstract Page No

09:45	OCTREOTIDE FOR DIABETIC RETINOPATHY D.S. Boyer, Los Angeles, CA, USA	10
09:55	EFFICACY AND SAFETY OF VITRASE(TM)-FINAL ANALYSIS E.L. Thomas, B.D. Kuppermann, Los Angeles, Irvine, CA, USA	10
10:05	RUBOXISTAURIN FOR NPDR AND DME B.D. Kuppermann, Irvine, CA, USA	
10:15	RETINAL NEUROPROTECTION J. Burke, Irvine, CA, USA	
10:25	DISCUSSION	
10:30	COFFEE BREAK, EXHIBITION AND POSTER VIEWING	

11:00 - 11:45

Hall A

OCULAR TOXICOLOGY OF TOPICAL AGENTS

Chairpersons: **Anthony J. Bron, UK**
Franz Grus, Germany

11:00	TOXICITY OF OCULAR PRESERVATIVES ON THE OCULAR SURFACE P.A. Asbell, S.P. Epstein, M. Ahdoot, C. Reddy, K. Yee, E. Marcus, New York, NY, USA	11
11:10	DRUG-INDUCED OCULAR SURFACE REACTIONS: PRESERVING THE EYEDROPS OR THE OCULAR SURFACE? C. Baudouin, Paris, France	11
11:20	THE EFFECTS OF PRESERVATIVES AND ANTI-GLAUCOMA DRUGS ON THE CORNEAL EPITHELIAL MIGRATION AND WOUND HEALING T. Nishida, Ube, Japan	11
11:30	THYROID HORMONE INFLUENCE IN THE LACRIMAL GLAND AND OCULAR SURFACE E.M. Rocha, A.C. Dias, C.M. Módulo, A.M. Braz, A.A. Jordão Jr., R. Bertazolli Filho, J.S. Marchini, Sao Paulo, Brazil	12
11:40	PANEL DISCUSSION	

Friday, March 31, 2006

09:45 - 10:30

Hall B

OPTIMIZING GLAUCOMA MANAGEMENT: IMPLICATIONS OF INTRAOCULAR PRESSURE AND OCULAR BLOOD FLOW

MERCK SPONSORED SYMPOSIUM

Chairperson: **Jost B. Jonas**, Germany

Abstract Page No

09:45	WELCOME AND INTRODUCTION J.B. Jonas , Heidelberg, Germany	
09:50	SHORT-TERM VERSUS MID-TERM 24-HOUR IOP EFFICACY COMPARISON BETWEEN LATANOPROST AND THE DORZOLAMIDE/TIMOLOL MALEATE FIXED COMBINATION A.G. Konstas , Thessaloniki, Greece	10
10:00	THE ROLE OF ALTERED HEMODYNAMICS IN OCULAR PYSIOPATHOLOGY L. Schmetterer , Vienna, Austria	10
10:10	PATHOGENESIS OF GLAUCOMA: IMPLICATIONS OF IOP AND OCULAR BLOOD FLOW A. Harris , Indianapolis, IN, USA	11
10:20	PANEL DISCUSSION Moderator: J.B. Jonas , Heidelberg, Germany	
10:30	COFFEE BREAK, EXHIBITION AND POSTER VIEWING	

11:00 - 11:45

Hall B

CHANGING PERSPECTIVES IN NEOVASCULAR AMD TREATMENT

PFIZER SPONSORED SYMPOSIUM

11:00	AETIOLOGY OF WET AMD: ROLE OF VEGF S. Grisanti , Tuebingen, Germany
11:15	PRINCIPLES OF ANTI-VEGF APTAMER THERAPY S. Grisanti , Tuebingen, Germany
11:30	CLINICAL TRIAL RESULTS J. Monés , Barcelona, Spain

Friday, March 31, 2006

11:45 - 12:30

Hall A

ANTIOXIDANTS

Chairpersons: **Paul S. Bernstein**, USA
Akihiro Ohira, Japan

Abstract Page No

- | | | |
|-------|---|----|
| 11:45 | BIOCHEMISTRY AND BIOPHYSICS OF LIPOFUSCIN AND THE MACULAR CAROTENOIDS IN AGE-RELATED MACULAR DEGENERATION: NEW INSIGHTS INTO AN OLD-AGE DISEASE
P.S. Bernstein , P. Bhosale, B. Serban, <i>Utah, AZ, USA</i> | 12 |
| 11:55 | MEASUREMENTS OF MACULAR CAROTENOID PIGMENTS BY RESONANCE RAMAN SPECTROSCOPY IN JAPANESE
A. Ohira , A. Obana, Y. Gohto, Y. Nagase, T. Hiramitsu, T. Hirano, Y. Hotta, K. Iseki, S. Mizuno, H. Fujii, M. Usui, P.S. Bernstein, <i>Izumo, Hamamatsu, Tokyo, Japan, Utah, AZ, USA</i> | 12 |
| 12:05 | PHOTOPROTECTIVE AND ANTIOXIDANT PROPERTIES OF MACULAR PIGMENTS
M. Wrona, M. Rozanowska, A. Pawlak, T. Sarna , <i>Krakow, Poland, Cardiff, UK</i> | 12 |
| 12:15 | PHOTOOXIDATION OF A2-PE, A PHOTORECEPTOR OUTER SEGMENT FLUOROPHORE, AND PROTECTION BY LUTEIN AND ZEAXANTHIN
J.R. Sparrow , S.R. Kim, K. Nakanishi, J. Zhou, Y. Itagaki, <i>New York, NY, USA</i> | 13 |
| 12:25 | DISCUSSION | |
| 12:30 | LUNCH BREAK, EXHIBITION AND POSTER VIEWING | |

14:00 - 14:45

Hall A

FROM BASIC SCIENCE TO CLINICAL PRACTICE IN GLAUCOMA

Chairpersons: **Peter Netland**, USA
Hagen Thieme, Germany

- | | | |
|-------|---|----|
| 14:00 | GENE THERAPY FOR GLAUCOMA
P.L. Kaufman , <i>Madison, WI, USA</i> | 14 |
| 14:10 | CILIARY BODY PROGENITOR CELLS
H.A. Quigley , <i>Baltimore, MD, USA</i> | 14 |
| 14:20 | ENDOGENOUS NEUROPROTECTION- HOW RETINAL GANGLION CELLS PROTECT THEMSELVES?
H. Levkovitch-Verbin , <i>Tel-Hashomer, Israel</i> | 15 |
| 14:30 | THE OPTIC NERVE HEAD - STRUCTURE AND SUSCEPTIBILITY FOR PROGRESSIVE DAMAGE
J.B. Jonas , <i>Heidelberg, Germany</i> | 15 |
| 14:40 | DISCUSSION | |

Friday, March 31, 2006

11:45 - 12:30

Hall B

RETISERT: FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT

BAUSCH & LOMB SPONSORED SESSION

Chairperson: **Baruch D. Kuppermann, USA**

Abstract Page No

- | | | |
|-------|---|----|
| 11:45 | NON INFECTIOUS POSTERIOR UVEITIS: EPIDEMIOLOGY AND CLASSIFICATION OF UVEITIS
M. Zierhut , Tuebingen, Germany | 13 |
| 11:53 | NON INFECTIOUS POSTERIOR UVEITIS: ADVANCES IN DIAGNOSIS OF UVEITIS
B. Bodaghi , Paris, France | 13 |
| 12:01 | FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT TO TREAT POSTERIOR UVEITIS: 2-YEAR RESULTS OF A MULTI-CENTER CLINICAL TRIAL
G. Jaffe, D. Martin, D. Callanan, B. Levy, A. Vitale , Durham, NC, Atlanta, GA, Arlington, TX, Rochester, NY, Salt Lake City, UT, USA | 13 |
| 12:09 | A MULTICENTRE, RANDOMISED, CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF AN INTRAVITREAL FLUOCINOLONE ACETONIDE (FA) IMPLANT COMPARED TO STANDARDISED THERAPY IN PATIENTS WITH NON INFECTIOUS POSTERIOR UVEITIS
C.E. Pavesio , B. Levy, C. Richard, K. Bairi, T. Comstock, London, UK, Rochester, NY, USA, Montpellier, Paris, France | 14 |
| 12:17 | FLUOCINOLONE IMPLANT SLOWS THE PROGRESSION OF DIABETIC RETINOPATHY
P.A. Pearson , Lexington, KY, USA | 14 |
| 12:25 | DISCUSSION | |
| 12:30 | LUNCH BREAK, EXHIBITION AND POSTER VIEWING | |

14:00 - 14:45

Hall B

EFFICACY AND SAFETY OF RANIBIZUMAB FOR THE TREATMENT OF NEOVASCULAR AMD

NOVARTIS SPONSORED SYMPOSIUM

Chairperson: **Michael Larsen, Denmark**

- | | | |
|-------|--|----|
| 14:00 | WELCOME AND INTRODUCTION
M. Larsen , Copenhagen, Denmark | |
| 14:05 | WHAT EFFECT DOES RANIBIZUMAB HAVE ON QUALITY-OF-LIFE IN PATIENTS WITH EXUDATIVE AMD?
PATIENT-REPORTED OUTCOMES USING THE VFQ-25 QUESTIONNAIRE
Y. Yang , Wolverhampton, UK | 15 |
| 14:15 | IS RANIBIZUMAB A SAFE OPTION FOR EXUDATIVE AMD? COMBINED SAFETY RESULTS FROM PHASE III CLINICAL STUDIES OF RANIBIZUMAB
D. Pauleikhoff , Münster, Germany | 15 |
| 14:25 | ARE THE BENEFITS OF RANIBIZUMAB FOR EXUDATIVE AMD MAINTAINED IN THE LONGER TERM? EFFICACY AND SAFETY RESULTS FROM THE MARINA STUDY
M. Larsen , Copenhagen, Denmark | 16 |
| 14:35 | PANEL DISCUSSION | |
| 14:45 | CONCLUSION
M. Larsen , Copenhagen, Denmark | |

Friday, March 31, 2006

Hall A

14:45 - 17:30

EXUDATIVE AMD

Chairpersons: **Peter K. Kaiser, USA**
Stephan Michels, Austria

Abstract Page No

14:45	CAND5 SIRNA FOR CNV / AMD B.D. Kuppermann, Irvine, CA, USA	62
14:55	A DOUBLE-MASKED, PLACEBO-CONTROLLED, DOSE ESCALATION, PHASE I STUDY OF INTRAVENOUS VEGF TRAP IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION Q.D. Nguyen, S.M. Shah, G. Hafiz, E. Holz, M. Benz, R. Rosen, J.A. Haller, S. Tatlipinar, K. Chu, J. Buskey, E. Furfine, D. Nadler, J. Cedarbaum, P.A. Campochiaro, Baltimore, MD, Houston, TX, New York, NY, Tarrytown, NY, USA	16
15:05	COMPARISON OF EARLY RESPONSE TO SYSTEMIC OR INTRAVITREAL BEVACIZUMAB (AVASTIN®) IN PATIENTS WITH NEOVASCULAR AMD S. Michels, P.J. Rosenfeld, W. Geitzenauer, F. Prager, U. Schmidt-Erfurth, Vienna, Austria, Miami, FL, USA	16
15:15	TREATMENT OF CHOROIDAL NEOVASCULARIZATION WITH PEGAPTANIB J. Monés, Barcelona, Spain	16
15:25	COMBRETASTATIN A4 PHOSPHATE FOR THE TREATMENT OF AMD Q.D. Nguyen, Baltimore, MD, USA	
15:30	COFFEE BREAK, EXHIBITION AND POSTER VIEWING	
16:00	SQUALAMINE LACTATE FOR THE TREATMENT OF EXUDATIVE MACULAR DEGENERATION E.L. Thomas, Los Angeles, CA, USA	18
16:10	ADPEDF TREATMENT OF EXUDATIVE AMD J.T. Stout, AdPEDF Study Group, Portland, OR, USA	18
16:20	A NOVEL FIRST-IN-CLASS, NON-INVASIVELY DELIVERED, MULTI-TARGETED (VEGFR2/SRC/PDGFR) KINASE INHIBITOR FOR THE TREATMENT OF AMD, PDR AND DME S. Yee, P.A. Campochiaro, L. Dellamary, M. Friedlander, G. Noronha, J. Hood, L. Scheppke, N. Umeda, B. Tam, R. Soll, La Jolla, CA, Baltimore, MD, USA	19
16:30	RNA INTERFERENCE WITH SIRNA-027 P.K. Kaiser, Cleveland, OH, USA	19
16:40	INTEGRIN ANTAGONISM IN THE TREATMENT OF EXUDATIVE AMD J.S. Heier, Boston, MA, USA	19
16:50	THE SCIENCE OF VEGF AND ITS IMPLICATIONS FOR THE TREATMENT OF AMD B. Katz, New York, NY, USA	19
17:00	LUCENTIS FOR CNV / AMD S. Michels, Vienna, Austria	
17:10	ANECORTAVE ACETATE (RETAANE®) UPDATE P.K. Kaiser, Cleveland, OH, USA	20
17:20	FRAGMENTS OF TRNA SYNTHETASES FOR INHIBITION OF NEOVASCULARIZATION M. Friedlander, La Jolla, CA, USA	20

Friday, March 31, 2006

14:45 - 15:30

Hall B

FREE PAPERS: GLAUCOMA

Chairpersons: **David S. Friedman**, USA
Keith Martin, UK

Abstract Page No

- 14:45 THE FAST ACTION OF PROSTAGLANDINE ANALOGUES ON THE CONVENTIONAL OUTFLOW SYSTEM
H. Thieme, L. Choritz, R. Rosenthal, N. Pfeiffer, *Mainz, Berlin, Germany* 17
- 14:52 SOME THOUGHTS ABOUT A NEW CONCEPT FOR EXAMINING OCULAR HYDRODYNAMICS
W.D. Ulrich, A. Moeller, C. Ulrich, G. Siebert, K.D. Wernecke, *Borna, Berlin, Germany* 17
- 14:59 THE USE OF FIBRIN ADHESIVE IN TRABECULECTOMY: A PILOT STUDY
I. Bahar, M. Lusky, D. Gatton, A. Robinson, R. Avisar, D. Weinberger, *Petach Tikva, Israel* 17
- 15:06 NONPENETRATING EXTERNAL TRABECULECTOMY FOR PRIMARY CONGENITAL GLAUCOMA
O. Roche, C. Orssaud, C. Parsa, J.L. Dufier, *Paris, France, Baltimore, MD, USA* 17
- 15:13 EFFECT OF LATANOPROST AND DORSOLAMIDE-TIMOLOL FIXED COMBINATION USED CONCOMITANTLY IN HIGH PRESSURE OPEN ANGLE GLAUCOMA CASES
O. Kayikcioglu, E.F. Başer, C. Güler, *Manisa, Turkey* 18
- 15:20 RGC NEUROPROTECTION WITH TRKA RECEPTOR AGONISTS IN AN ANIMAL MODEL OF GLAUCOMA
H.U. Saragovi, S. Zi-Hua, F. Lebrun-Julien, A. DiPolo, **G. Cumberlidge**, *Montreal, Canada* 18
- 15:27 DISCUSSION
- 15:30 **COFFEE BREAK, EXHIBITION AND POSTER VIEWING**

16:00 - 16:45

Hall B

NOVEL MECHANISMS FOR PHARMCOLOGICAL INHIBITION OF NEURONAL DEATH

Chairpersons: **Wolf Lagrèze**, Germany
Leonard A. Levin, USA

- 16:00 NEUROPROTECTION IN GLAUCOMA: MAINTAINING GANGLION CELL MITOCHONDRIAL FUNCTION
N.N. Osborne, *Oxford, UK* 20
- 16:10 NEUROPROTECTION OF RETINAL GANGLION CELLS
M. Bähr, *Göttingen, Germany* 20
- 16:20 NEURONAL REGENERATION: WHAT CAN WE LEARN FROM THE SPINAL CORD?
I.C. Maier, M.E. Schwab, *Zurich, Switzerland* 21
- 16:30 NOVEL MECHANISMS FOR THE PHARMACOLOGICAL INHIBITION OF AXONALLY-MEDIATED NEURONAL DEATH
K.R. Martin, *Cambridge, UK* 21
- 16:40 DISCUSSION

Friday, March 31, 2006

16:45 - 17:30

Hall B

IN VITRO APPROACHES TO OCULAR DISEASES & DRUG DISCOVERY

Chairperson: **Neeraj Agarwal, USA**

Abstract Page No

16:45	STRATEGIES OF NEUROPROTECTION IN GLAUCOMA N. Agarwal , D.M. Kumar, <i>Fort Worth, TX, USA</i>	21
16:55	THE ROLE OF CAMKII IN CELL DEATH AND SURVIVAL PATHWAYS OF RGC-5 CELLS N.G. Cooper , X. Li, A. Khalyfa, W. Fan, <i>Louisville, KY, USA</i>	21
17:05	IN VITRO ASSAYS - FROM SCREENS TO GENES: ROLE IN OCULAR DRUG DISCOVERY G. Prasanna , <i>La Jolla, CA, USA</i>	22
17:15	AQUAPORIN WATER CHANNELS: A PROMISING TARGET FOR DRUG DEVELOPMENT R.V. Patil , <i>Fort Worth, TX, USA</i>	22
17:25	OPTIC NERVE ASTROCYTES: A MODEL FOR CELL SIGNALING AND DRUG TARGETS FOR GLAUCOMA T. Yorio , A. Dibas, S. He, R. Krishnamoorthy, <i>Fort Worth, TX, USA</i>	22